Dual blockade of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)

PURPOSE: Targeting a single pathway in pancreatic adenocarcinoma (PC) is unlikely to impact its natural history. We tested the hypothesis that simulataneous targeting of the EGFR and IGF-1R pathways would significantly improve progression free survival (PFS) by abrogating reciprocal signaling that p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Philip, Philip A., Goldman, Bryan, Ramanathan, Ramesh K., Lenz, Heinz-Josef, Lowy, Andrew M., Whitehead, Robert P., Wakatsuki, Takeru, Iqbal, Syma, Gaur, Rakesh, Benedetti, Jacqueline K., Blanke, Charles D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4284963/
https://ncbi.nlm.nih.gov/pubmed/25041791
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28744
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados